Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Robertson Stephens Wealth Management LLC

Robertson Stephens Wealth Management LLC cut its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 6.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 172,186 shares of the company’s stock after selling 11,500 shares during the period. Robertson Stephens Wealth Management LLC owned 0.12% of Adaptive Biotechnologies worth $1,032,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. JTC Employer Solutions Trustee Ltd acquired a new position in Adaptive Biotechnologies in the third quarter valued at approximately $26,000. Ashton Thomas Securities LLC acquired a new position in Adaptive Biotechnologies in the third quarter valued at approximately $34,000. KBC Group NV acquired a new position in Adaptive Biotechnologies in the fourth quarter valued at approximately $50,000. GAMMA Investing LLC acquired a new position in Adaptive Biotechnologies during the fourth quarter worth $59,000. Finally, Townsquare Capital LLC acquired a new position in Adaptive Biotechnologies during the third quarter worth $56,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Trading Down 0.5 %

Adaptive Biotechnologies stock opened at $8.01 on Friday. Adaptive Biotechnologies Co. has a twelve month low of $2.28 and a twelve month high of $8.33. The stock’s fifty day simple moving average is $6.76 and its 200-day simple moving average is $5.47. The firm has a market capitalization of $1.18 billion, a P/E ratio of -5.98 and a beta of 1.50.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ADPT shares. BTIG Research upped their price target on Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler upped their price target on Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, The Goldman Sachs Group upped their price target on Adaptive Biotechnologies from $5.50 to $7.50 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.